Beyfortus™—
Now ACIP Recommended!
View press release
is NOW APPROVED!

Beyfortus™ is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in1:

Neonates and infants icon

Neonates and infants born during or entering their first RSV season

Infant icon

Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season

The recommended dosage of Beyfortus for neonates and infants born during or entering their first RSV season is based on body weight and is administered as a single intramuscular (IM) injection.

For children up to 24 months of age who remain at increased risk for severe RSV disease in their second RSV season, the recommended dosage of Beyfortus is a single 200 mg dose administered as two IM injections (2 x 100 mg).

Based on clinical data, the duration of protection offered by a single dose of Beyfortus extends through 5 months.

Bar graph icon
Learn about Beyfortus clinical trials
Syringe icon
Explore how to administer Beyfortus
Customer service icon
Get information and request a representative
IMPORTANT SAFETY INFORMATION
Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
IMPORTANT SAFETY INFORMATION
Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions
INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

Reference: 1. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.